Antipodes Partners’s Thermo Fisher Scientific TMO Stock Holding History

Antipodes Partners’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-131	Closed	-$75.9K	–	151
2025 Q4	$75.9K	Buy	131 +33	+34%	+$18.7K	﹤0.01%	94
2025 Q3	$47.5K	Buy	+98	New	+$45.6K	﹤0.01%	95
2022 Q4	–	Sell	-5,381	Closed	-$2.73M	–	72
2022 Q3	$2.73M	Buy	+5,381	New	+$3.01M	0.11%	37

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Antipodes Partners's TMO Position: Q1 2026 in Review

Antipodes Partners sold out of Thermo Fisher Scientific (TMO) in Q1 2026, closing a stake of 131 shares — an estimated $75.9K sold.

Antipodes Partners first reported a position in TMO in Q3 2022 and held it in 3 quarters. The position peaked at $2.73M in Q3 2022. 2,595 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

Antipodes Partners reported no remaining Thermo Fisher Scientific position as of Q1 2026 after selling out during the quarter.
Antipodes Partners sold 131 Thermo Fisher Scientific shares in Q1 2026, an estimated $75.9K.
Antipodes Partners first reported a position in Thermo Fisher Scientific in Q3 2022 and held it in 3 quarters.
Antipodes Partners's Thermo Fisher Scientific position peaked at $2.73M in Q3 2022.
2,595 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.